Immix Biopharma (IMMX) Enterprise Value (2021 - 2026)

Immix Biopharma has reported Enterprise Value for 7 years, with the latest figure at -$90.6 million in Q1 2026.

• Quarterly Enterprise Value fell 468.93% year-over-year to -$90.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$90.6 million (down 468.93% YoY) and the FY2025 annual result came in at -$100.4 million, down 467.97% from the prior year.
• Enterprise Value climbed to -$90.6 million in Q1 2026 per IMMX's latest filing, from -$100.4 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$11.5 million in Q1 2023 and troughed at -$100.4 million in Q4 2025.
• A 5-year average of -$26.8 million and a median of -$17.7 million in 2023 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2025 and 2026: Enterprise Value jumped 51.62% in 2025, then tumbled 468.93% in 2026.
• Over 5 years, Enterprise Value stood at -$13.4 million in 2022, then plunged by 31.81% to -$17.7 million in 2023, then grew by 0.17% to -$17.7 million in 2024, then slumped by 467.97% to -$100.4 million in 2025, then increased by 9.81% to -$90.6 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$90.6 million, -$100.4 million, and -$15.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.